174 related articles for article (PubMed ID: 20657706)
1. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.
Hooker JM; Kim SW; Alexoff D; Xu Y; Shea C; Reid A; Volkow N; Fowler JS
ACS Chem Neurosci; 2010; 1(1):65-73. PubMed ID: 20657706
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.
Wang C; Eessalu TE; Barth VN; Mitch CH; Wagner FF; Hong Y; Neelamegam R; Schroeder FA; Holson EB; Haggarty SJ; Hooker JM
Am J Nucl Med Mol Imaging; 2013; 4(1):29-38. PubMed ID: 24380043
[TBL] [Abstract][Full Text] [Related]
3. Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.
Seo YJ; Kang Y; Muench L; Reid A; Caesar S; Jean L; Wagner F; Holson E; Haggarty SJ; Weiss P; King P; Carter P; Volkow ND; Fowler JS; Hooker JM; Kim SW
ACS Chem Neurosci; 2014 Jul; 5(7):588-96. PubMed ID: 24780082
[TBL] [Abstract][Full Text] [Related]
4. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
5. Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?
Joshi EM; Need A; Schaus J; Chen Z; Benesh D; Mitch C; Morton S; Raub TJ; Phebus L; Barth V
ACS Chem Neurosci; 2014 Dec; 5(12):1154-63. PubMed ID: 25247893
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.
Elsinga PH; Hendrikse NH; Bart J; van Waarde A; Vaalburg W
Mol Imaging Biol; 2005; 7(1):37-44. PubMed ID: 15912274
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of an
Tago T; Toyohara J; Ishii K
ACS Chem Neurosci; 2021 Feb; 12(4):746-755. PubMed ID: 33502174
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
[TBL] [Abstract][Full Text] [Related]
10. Validation of in vitro cell-based human blood-brain barrier model using clinical positron emission tomography radioligands to predict in vivo human brain penetration.
Mabondzo A; Bottlaender M; Guyot AC; Tsaouin K; Deverre JR; Balimane PV
Mol Pharm; 2010 Oct; 7(5):1805-15. PubMed ID: 20795735
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data.
Bergström M; Yates R; Wall A; Kågedal M; Syvänen S; Långström B
J Pharmacokinet Pharmacodyn; 2006 Feb; 33(1):75-91. PubMed ID: 16402287
[TBL] [Abstract][Full Text] [Related]
12. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
Elsinga PH; Hendrikse NH; Bart J; Vaalburg W; van Waarde A
Curr Pharm Des; 2004; 10(13):1493-503. PubMed ID: 15134571
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.
Shein NA; Shohami E
Mol Med; 2011; 17(5-6):448-56. PubMed ID: 21274503
[TBL] [Abstract][Full Text] [Related]
14. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
Lanzillotta A; Pignataro G; Branca C; Cuomo O; Sarnico I; Benarese M; Annunziato L; Spano P; Pizzi M
Neurobiol Dis; 2013 Jan; 49():177-89. PubMed ID: 22971966
[TBL] [Abstract][Full Text] [Related]
15.
Kommidi H; Tosi U; Maachani UB; Guo H; Marnell CS; Law B; Souweidane MM; Ting R
ACS Med Chem Lett; 2018 Feb; 9(2):114-119. PubMed ID: 29456798
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases.
Lillico R; Sobral MG; Stesco N; Lakowski TM
J Proteomics; 2016 Feb; 133():125-133. PubMed ID: 26721445
[TBL] [Abstract][Full Text] [Related]
18. Determination of chidamide in rat plasma and cerebrospinal fluid.
Yang H; Li C; Chen Z; Mou H; Gu L
Regul Toxicol Pharmacol; 2018 Oct; 98():24-30. PubMed ID: 30008379
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
